{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-106545","form_type":"8-K","ticker":"OLMA","cik":"0001750284","company_name":"Olema Pharmaceuticals, Inc.","filed_at":"2025-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.871107+00:00","generated_at":"2026-05-17T15:35:36.598856+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Olema Q2 net loss $43.8M, selects 90 mg palazestrant dose for Phase 3 trials, cash $361.9M","bullets":["Q2 net loss $43.8M vs $30.4M YoY; increase driven by $10M Aurigene milestone and higher R&D for late-stage trials.","Selected 90 mg once-daily palazestrant for OPERA-01 Part 2 and OPERA-02 frontline combo trial with ribociclib.","OPERA-01 top-line data expected H2 2026; OPERA-02 initiation on track for Q3 2025.","Cash, equivalents, and marketable securities $361.9M as of June 30, 2025.","Mature palazestrant+ribociclib Phase 1b/2 data to be presented at ESMO 2025; OP-3136 Phase 1 enrolling."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-106545","json":"https://secwatch.observer/filing/0000950170-25-106545.json","markdown":"https://secwatch.observer/filing/0000950170-25-106545.md","text":"https://secwatch.observer/filing/0000950170-25-106545.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/0000950170-25-106545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-20250811.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T15:35:36.598856+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}